French CRO specializing in early-phase clinical trials for psychiatric, neurological, and metabolic disorders within large European research consortia.
BIOTRIAL is a French contract research organization (CRO) based in Rennes, specializing in early-phase clinical trials with a strong focus on central nervous system (CNS) disorders and metabolic diseases. In H2020 projects, they contribute clinical pharmacology expertise — running controlled human studies, collecting biomarker data, and supporting translational research that bridges preclinical findings to patient outcomes. Their work spans psychiatric conditions (schizophrenia, depression, Alzheimer's) and metabolic multimorbidity (diabetes, obesity), positioning them as a clinical partner for complex, multi-domain health studies.
Core contributor to both PRISM (2016-2019) and PRISM 2 (2021-2024), focused on intermediate stratified markers for psychiatric disorders including Alzheimer's, schizophrenia, and major depression.
All three projects (PRISM, PRIME, PRISM 2) involve clinical study components in neuropsychiatric and metabolic domains, consistent with their CRO role.
Participant in PRIME project addressing insulin resistance, diabetes type 2, obesity, and metabolic syndrome comorbidities including dementia and compulsivity.
PRISM 2 explicitly targets translational neuroscience, digital biomarkers, and quantitative biology — suggesting a move toward data-driven clinical assessment.
BIOTRIAL's H2020 journey began with psychiatric stratification research through PRISM (2016), focusing on identifying intermediate markers for mental health conditions. By 2020-2021, their scope broadened in two directions: metabolic-psychiatric comorbidities (PRIME, linking insulin disorders to dementia and compulsivity) and more advanced measurement approaches including digital biomarkers and quantitative biology (PRISM 2). The trajectory shows a clear shift from traditional psychiatric clinical trials toward interdisciplinary, data-enriched studies that connect metabolic and neurological conditions.
BIOTRIAL is moving toward interdisciplinary clinical studies that link metabolic and neuropsychiatric conditions, with increasing use of digital biomarkers and quantitative methods — a valuable direction for precision psychiatry consortia.
BIOTRIAL operates exclusively as a consortium participant, never as coordinator — consistent with their role as a specialized CRO providing clinical trial infrastructure and expertise to researcher-led projects. With 43 unique partners across 12 countries from just 3 projects, they integrate into large, multi-national consortia (the IMI2 projects typically involve 15-30 partners). This makes them an accessible, low-friction partner: they bring specific clinical capabilities without competing for scientific leadership.
Despite only three projects, BIOTRIAL has built a broad network of 43 partners across 12 countries, reflecting participation in large IMI-style public-private consortia. Their network spans academic hospitals, pharmaceutical companies, and research institutes across Western Europe.
BIOTRIAL's value lies at the intersection of clinical trial execution and neuroscience research — they are not just a generic CRO but one with deep domain expertise in CNS and psychiatric conditions. Their participation in both PRISM iterations shows trusted, repeat engagement in a niche area. For consortium builders, they offer a rare combination: an SME with clinical trial infrastructure specifically tuned for neuropsychiatric and metabolic disorder studies, based in France's life sciences hub of Rennes.
